Results 91 to 100 of about 14,464 (157)

Error-resilient scheme for wavelet video codec using automatic ROI detection and Wyner-Ziv coding over packet erasure channel [PDF]

open access: yes, 2010
This is the author's accepted manuscript. The final published article is available from the link below. Copyright @ 2010 IEEE. Personal use of this material is permitted.
Loo, K.K.   +17 more
core   +1 more source

Ziv-aflibercept in metastatic colorectal cancer

open access: yesBiologics: Targets & Therapy, 2013
Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become
Patel A, Sun W
doaj  

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

open access: yesClinical Ophthalmology, 2023
Suthasinee Sinawat,1,2 Suthasinee Hemanak,1 Kwanchanok Chanthowong,1 Supat Sinawat,3 Yosanan Yospaiboon1,2 1Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 2KKU Eye Center, Khon Kaen University, Khon Kaen ...
Sinawat S   +4 more
doaj  

Safety of Intravitreal ziv-aflibercept

open access: yes, 2017
Purpose: 1. To evaluate the viability of ARPE-19 human retinal pigment epithelial cells after exposure to ziv-aflibercept 12.5 and 25 mg/mL; 2. To evaluate the safety of intravitreal ziv-aflibercept in an experimental rabbit model; 3.
Dias, João Rafael de Oliveira [UNIFESP]
core  

The short- and long-range RNA-RNA Interactome of SARS-CoV-2. Ziv et al.

open access: yes
Supplemental files accompanying Ziv et al.'s paper "The short- and long-range RNA-RNA Interactome of SARS-CoV ...
Ziv, O
core   +1 more source

North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo (pbo) plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.

open access: yes, 2013
465 Background: Ziv-aflibercept (trade name ZALTRAP; known outside the US as aflibercept) is a new multiple angiogenic inhibitor that prevents VEGF-A, VEGF-B and PLGF from binding their receptors.
Michael L. Andria   +6 more
core   +1 more source

To laser or not?

open access: yesIndian Journal of Ophthalmology, 2018
A 64-year-old male patient presented to the clinic with diminished vision in his right eye for the past 2 years. Examination revealed a best-corrected visual acuity (BCVA) of counting fingers at 1 m with a scarred choroidal neovascular membrane (CNVM) in
Vishal Govindhari, Jay Chhablani
doaj   +1 more source

Budgetary impact of adding ziv-aflibercept to a United States health plan formulary as a post-oxaliplatin biologic option for patients with metastatic colorectal cancer (mCRC).

open access: yes, 2015
765 Background: To assess the economic impact of the availability of ziv-aflibercept for patients with mCRC following disease progression after oxaliplatin, a user-adaptable budget impact model was developed for payers, based on use of 5-fluorouracil ...
Stephen F. Thompson   +4 more
core   +1 more source

Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

open access: yes, 2016
4 Background: FOLFOX has RR 53% and PFS 6.8 months in MEGA (CALGB 80403). VEGF inhibition has improved survival in some but not all randomized trials in MEGA.
Charles S. Fuchs   +17 more
core   +1 more source

Role of Optical Coherence Tomography-angiography in Diagnosis and Monitoring Activity of Macular Telangiectasia-associated Choroidal Neovascular Membrane

open access: yesDelhi Journal of Ophthalmology
We report the case of a 62-year-old female diagnosed with Type 2A, Stage 5 macular telangiectasia (MacTel). The right eye showed a scarred choroidal neovascular membrane (CNVM) while the left eye had an active CNVM, confirmed with optical coherence ...
Mohd Azaz Quraishi   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy